Reminder of REGENXBIO Securities Class Action
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy RGNX?
Source: Globenewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ: RGNX) securities between February 9, 2022, and January 27, 2026, to apply as lead plaintiffs by April 14, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, ensuring legal support without financial burden for the investors.
- Case Background: The lawsuit alleges that defendants provided false and misleading information regarding the development of REGENXBIO's RGX-111 gene therapy, resulting in investor losses when the true details emerged, highlighting the importance of protecting investor rights.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and success in this field.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGNX
Wall Street analysts forecast RGNX stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.530
Low
19.00
Averages
29.71
High
45.00
Current: 8.530
Low
19.00
Averages
29.71
High
45.00
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
REGENXBIO to Host Conference Call for Q4 and Full Year Results
- Conference Call Announcement: REGENXBIO will host a conference call on March 5, 2026, at 8:00 a.m. ET to discuss its Q4 and full-year financial results for the year ended December 31, 2025, which is expected to attract significant attention from investors and analysts.
- Webcast Registration: Listeners can register for the webcast via the provided link, while analysts wishing to participate in the Q&A session must use the designated link, ensuring transparency and interactivity in the discussion.
- Replay Availability: A replay of the webcast will be available approximately two hours after the call concludes on the company's investor website, facilitating access to key information for investors who cannot participate live, thereby enhancing information accessibility.
- Company Background: Since its founding in 2009, REGENXBIO has been dedicated to improving lives through gene therapy, advancing a late-stage pipeline targeting rare and retinal diseases, showcasing its innovative potential and market impact in the biotechnology sector.
See More
Class Action Lawsuits Filed Against PayPal and REGENXBIO
- PayPal Lawsuit Overview: A class action lawsuit against PayPal alleges that from February 25, 2025, to February 2, 2026, the company misled investors about its revenue outlook, resulting in a stock price drop of over 20% following disappointing earnings announced on February 3, 2026.
- CEO Transition Impact: The lawsuit highlights the transition of CEO James Alexander Chriss during the earnings announcement, exacerbating market concerns about the company's future and reflecting instability in management.
- REGENXBIO Lawsuit Background: The class action against REGENXBIO involves its gene therapy RGX-111, accusing the company of disseminating false information about trial success from February 9, 2022, to January 27, 2026, with the FDA placing a clinical hold on January 28, 2026, causing a 17.8% stock price drop in one day.
- Market Reaction Analysis: Both lawsuits indicate a decline in investor confidence regarding the companies' future prospects, with stock price volatility for PayPal and REGENXBIO reflecting heightened market scrutiny on corporate governance and operational transparency, potentially affecting their long-term investment appeal.
See More
Reminder of REGENXBIO Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ: RGNX) securities between February 9, 2022, and January 27, 2026, to apply as lead plaintiffs by April 14, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, ensuring legal support without financial burden for the investors.
- Case Background: The lawsuit alleges that defendants provided false and misleading information regarding the development of REGENXBIO's RGX-111 gene therapy, resulting in investor losses when the true details emerged, highlighting the importance of protecting investor rights.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and success in this field.
See More
FDA Tightens Stance on Rare Disease Drug Approvals
- FDA Policy Tightening: In an interview, FDA Commissioner Makary defended the agency's stricter stance on rare disease drug approvals, mentioning a product that showed no benefit in a randomized trial and had associated morbidity, indicating a more cautious approach that could slow future drug approvals.
- uniQure Stock Plunge: Following Makary's comments, uniQure's shares plummeted 32% on Thursday, reflecting market concerns over the approval prospects of its Huntington's disease gene therapy AMT-130, especially after the FDA deemed early trial data insufficient to support an application.
- Market Sentiment Shift: Despite the stock drop, retail sentiment around QURE on Stocktwits shifted from 'bearish' to 'bullish' within 24 hours, indicating investor optimism about the company's plans to communicate with the FDA regarding a path forward for approval.
- Competitive Drug Analysis: Analysts noted that Makary's comments could refer to either uniQure's AMT-130 or Regenxbio's RGX-121, the latter of which was not approved by the FDA due to insufficient evidence of effectiveness, highlighting the agency's rigorous scrutiny that may impact the entire industry's R&D direction.
See More
REGENXBIO Investors Class Action Notice Issued
- Class Action Initiated: The Portnoy Law Firm has notified REGENXBIO investors of a class action lawsuit for those who purchased securities between February 9, 2022, and January 27, 2026, with a deadline of April 14, 2026, for filing a lead plaintiff motion to protect their legal rights.
- Clinical Trial Issues: On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its RGX-111 gene therapy due to the discovery of an intraventricular CNS tumor in a trial participant, resulting in a nearly 18% drop in stock price, raising concerns about the safety and efficacy of its clinical studies.
- Legal Consultation Services: The Portnoy Law Firm offers complimentary case evaluations and encourages investors to contact attorney Lesley F. Portnoy via phone or email to discuss options for recovering losses, demonstrating the firm's commitment to investor rights.
- Company Background: REGENXBIO is a clinical-stage biotechnology company focused on gene therapies, developing RGX-111 for treating severe Mucopolysaccharidosis Type I (Hurler syndrome), with its market prospects now jeopardized by ongoing legal challenges.
See More
REGENXBIO to Host Conference Call for Q4 and Full Year Financial Results
- Conference Call Announcement: REGENXBIO will host a conference call on March 5, 2026, at 8:00 a.m. ET to discuss its Q4 and full-year financial results for 2025, which is expected to attract significant attention from investors and analysts.
- Webcast Registration: Participants can register for the webcast via a provided link, ensuring timely access to financial results and operational highlights, thereby enhancing transparency and investor confidence.
- Q&A Session Participation: Analysts can participate in a Q&A session through a specific link, which not only provides them with direct interaction opportunities with management but also aids in enhancing market understanding of the company's future developments.
- Replay Availability: A replay of the call will be available approximately two hours after its conclusion on the company's investor website, ensuring that investors who could not participate live can access key information, further promoting information dissemination and transparency.
See More
REGENXBIO to Host Conference Call for Q4 and Full Year Results
- Conference Call Announcement: REGENXBIO will host a conference call on March 5, 2026, at 8:00 a.m. ET to discuss its Q4 and full-year financial results for the year ended December 31, 2025, which is expected to attract significant attention from investors and analysts.
- Webcast Registration: Listeners can register for the webcast via the provided link, while analysts wishing to participate in the Q&A session must use the designated link, ensuring transparency and interactivity in the discussion.
- Replay Availability: A replay of the webcast will be available approximately two hours after the call concludes on the company's investor website, facilitating access to key information for investors who cannot participate live, thereby enhancing information accessibility.
- Company Background: Since its founding in 2009, REGENXBIO has been dedicated to improving lives through gene therapy, advancing a late-stage pipeline targeting rare and retinal diseases, showcasing its innovative potential and market impact in the biotechnology sector.
See More
Class Action Lawsuits Filed Against PayPal and REGENXBIO
- PayPal Lawsuit Overview: A class action lawsuit against PayPal alleges that from February 25, 2025, to February 2, 2026, the company misled investors about its revenue outlook, resulting in a stock price drop of over 20% following disappointing earnings announced on February 3, 2026.
- CEO Transition Impact: The lawsuit highlights the transition of CEO James Alexander Chriss during the earnings announcement, exacerbating market concerns about the company's future and reflecting instability in management.
- REGENXBIO Lawsuit Background: The class action against REGENXBIO involves its gene therapy RGX-111, accusing the company of disseminating false information about trial success from February 9, 2022, to January 27, 2026, with the FDA placing a clinical hold on January 28, 2026, causing a 17.8% stock price drop in one day.
- Market Reaction Analysis: Both lawsuits indicate a decline in investor confidence regarding the companies' future prospects, with stock price volatility for PayPal and REGENXBIO reflecting heightened market scrutiny on corporate governance and operational transparency, potentially affecting their long-term investment appeal.
See More
Reminder of REGENXBIO Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ: RGNX) securities between February 9, 2022, and January 27, 2026, to apply as lead plaintiffs by April 14, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, ensuring legal support without financial burden for the investors.
- Case Background: The lawsuit alleges that defendants provided false and misleading information regarding the development of REGENXBIO's RGX-111 gene therapy, resulting in investor losses when the true details emerged, highlighting the importance of protecting investor rights.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and success in this field.
See More
FDA Tightens Stance on Rare Disease Drug Approvals
- FDA Policy Tightening: In an interview, FDA Commissioner Makary defended the agency's stricter stance on rare disease drug approvals, mentioning a product that showed no benefit in a randomized trial and had associated morbidity, indicating a more cautious approach that could slow future drug approvals.
- uniQure Stock Plunge: Following Makary's comments, uniQure's shares plummeted 32% on Thursday, reflecting market concerns over the approval prospects of its Huntington's disease gene therapy AMT-130, especially after the FDA deemed early trial data insufficient to support an application.
- Market Sentiment Shift: Despite the stock drop, retail sentiment around QURE on Stocktwits shifted from 'bearish' to 'bullish' within 24 hours, indicating investor optimism about the company's plans to communicate with the FDA regarding a path forward for approval.
- Competitive Drug Analysis: Analysts noted that Makary's comments could refer to either uniQure's AMT-130 or Regenxbio's RGX-121, the latter of which was not approved by the FDA due to insufficient evidence of effectiveness, highlighting the agency's rigorous scrutiny that may impact the entire industry's R&D direction.
See More
REGENXBIO Investors Class Action Notice Issued
- Class Action Initiated: The Portnoy Law Firm has notified REGENXBIO investors of a class action lawsuit for those who purchased securities between February 9, 2022, and January 27, 2026, with a deadline of April 14, 2026, for filing a lead plaintiff motion to protect their legal rights.
- Clinical Trial Issues: On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its RGX-111 gene therapy due to the discovery of an intraventricular CNS tumor in a trial participant, resulting in a nearly 18% drop in stock price, raising concerns about the safety and efficacy of its clinical studies.
- Legal Consultation Services: The Portnoy Law Firm offers complimentary case evaluations and encourages investors to contact attorney Lesley F. Portnoy via phone or email to discuss options for recovering losses, demonstrating the firm's commitment to investor rights.
- Company Background: REGENXBIO is a clinical-stage biotechnology company focused on gene therapies, developing RGX-111 for treating severe Mucopolysaccharidosis Type I (Hurler syndrome), with its market prospects now jeopardized by ongoing legal challenges.
See More
REGENXBIO to Host Conference Call for Q4 and Full Year Financial Results
- Conference Call Announcement: REGENXBIO will host a conference call on March 5, 2026, at 8:00 a.m. ET to discuss its Q4 and full-year financial results for 2025, which is expected to attract significant attention from investors and analysts.
- Webcast Registration: Participants can register for the webcast via a provided link, ensuring timely access to financial results and operational highlights, thereby enhancing transparency and investor confidence.
- Q&A Session Participation: Analysts can participate in a Q&A session through a specific link, which not only provides them with direct interaction opportunities with management but also aids in enhancing market understanding of the company's future developments.
- Replay Availability: A replay of the call will be available approximately two hours after its conclusion on the company's investor website, ensuring that investors who could not participate live can access key information, further promoting information dissemination and transparency.
See More
